Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JCAR017 in Pediatric r/r B-ALL and B-NHL
NCT03743246Phase 2Terminated
- Sponsor
- Celgene Corporation
- Start
- Oct 2018
- Primary completion
- Jan 2024
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 6
01
Overview
Phase 2, open-label, single-arm trial of lisocabtagene maraleucel in B cell acute lymphoblastic leukemia (B-ALL) and B-cell non-Hodgkin lymphoma, sponsored by Celgene Corporation. Primary endpoints: Treatment Emergent Adverse Events up to 30 Days Post JCAR017 Infusion, Dose Limiting Toxicities at 28 days and 1 more. Started Oct 2018; status: terminated.
02
Drugs
lisocabtagene maraleucel
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT03743246.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03743246.